Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netoglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netoglitazone SCHEMBL29434827 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29361540 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL20125596 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL142658 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29355957 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL20125595 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL8877880 | 0.99 | FFAR1 (0.54) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| SCHEMBL7514721 | 0.89 | PTPN1 (0.52) | FFAR1PPARAPTPN1PTPN2CDC25B | |
| SCHEMBL4239883 | 0.89 | MAOB (0.51) | FFAR1PPARAPTPN1PTPN2CDC25B | |
| SCHEMBL7634850 | 0.88 | FFAR1 (0.57) | FFAR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| US-20240084387-A1 | GENETIC VARIANTS ASSOCIATED WITH LOCAL FAT DEPOSITION TRAITS FOR THE TREATMENT OF HERITABLE METABOLIC DISORDERS | THE BROAD INSTITUTE, INC. | 2024-03-14 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| US-11746354-B2 | Homology dependent repair genome editing | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2023-09-05 | — | — | US | claimed |
| US-20220170034-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE TECHNOLOGY, INC. | 2022-06-02 | — | — | US | claimed |
| EP-3999103-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | Inari Agriculture, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545705-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2026-02-10 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12522822-B2 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3999103-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | Inari Agriculture, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220096435-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| US-11261212-B2 | IBAT inhibitors for the treatment of liver diseases | ALBIREO AB (SE) | 2022-03-01 | — | — | US | disclosed |
| US-11248031-B2 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-15 | — | — | US | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096435-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | PPARG 46/4885FFAR1 392/4885PPARA 50/4885 |
| US-11248031-B2 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides | FGF1, HDGF, FGF2 | PPARG 1350/4885FFAR1 1181/4885PPARA 1097/4885 |
| US-12545705-B2 | IBAT inhibitors for the treatment of liver diseases | SLC10A2, SLC10A1, CLIC1 | PPARG 2957/4885FFAR1 597/4885PPARA 2508/4885 |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | PPARG 2063/4885FFAR1 2754/4885PPARA 1810/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | PPARG 97/4885FFAR1 25/4885PPARA 96/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | PPARG 2056/4885FFAR1 2353/4885PPARA 2061/4885 |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | PPARG 46/4885FFAR1 392/4885PPARA 50/4885 |
| US-11261212-B2 | IBAT inhibitors for the treatment of liver diseases | GPR119, SLC10A1, SLC10A2 | PPARG 125/4885FFAR1 193/4885PPARA 373/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | PPARG 141/4885FFAR1 397/4885PPARA 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.